Exact Mass: 313.18215919999994
Exact Mass Matches: 313.18215919999994
Found 421 metabolites which its exact mass value is equals to given mass value 313.18215919999994,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Armepavine
C19H23NO3 (313.16778480000005)
Armepavine is a member of isoquinolines. (-)-Armepavine is a natural product found in Berberis integerrima, Aconitum variegatum, and other organisms with data available. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades[1]. Armepavine, an active compound from Nelumbo nucifera, exerts not only anti-inflammatory effects on human peripheral blood mononuclear cells, but also immunosuppressive effects on T lymphocytes and on lupus nephritic mice. Armepavine inhibits TNF-α-induced MAPK and NF-κB signaling cascades[1].
Ethylmorphine
C19H23NO3 (313.16778480000005)
A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products). R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics S - Sensory organs > S01 - Ophthalmologicals
Heliotrine
Origin: Plant; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2319 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 120 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 140 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 160 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 170 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 130 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 110 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 100 CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 150
(+)-Erysotrine
C19H23NO3 (313.16778480000005)
(+)-Erysotrine is found in green vegetables. (+)-Erysotrine is an alkaloid from a wide range of Erythrina species including Erythrina abyssinica, Erythrina arborescens, Erythrina atitlanensis, Erythrina blakei, Erythrina caffra, Erythrina coralloides, Erythrina crista-galli, Erythrina flabelliformis, Erythrina folkersii, Erythrina fusca (gallito), Erythrina goldmanii, Erythrina guatemalensis, Erythrina herbacea, Erythrina lithosperma, Erythrina livingstoniana, Erythrina macrophylla, Erythrina mulungu, Erythrina oliviae, Erythrina poeppigiana, Erythrina senegalensis, Erythrina steyermarkii, Erythrina suberosa, Erythrina tajumulcensis, Erythrina variegata and Erythrina zeher
3-Methoxyestra-1,3,5(10)-trien-16-oximino-17-one
C19H23NO3 (313.16778480000005)
6-O-Methylcodeine
C19H23NO3 (313.16778480000005)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids 6-O-Methylcodeine is a minor alkaloid of Papaver somniferum (opium poppy
9-Decenoylcarnitine
9-Decenoylcarnitine is an acylcarnitine. More specifically, it is an 9-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 9-decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]
Reboxetine
C19H23NO3 (313.16778480000005)
Reboxetine is an antidepressant drug used in the treatment of clinical depression, panic disorder and ADD/ADHD. Its mesylate (i.e. methanesulfonate) salt is sold under tradenames including Edronax, Norebox, Prolift, Solvex, Davedax or Vestra. Reboxetine has two chiral centers, but it only exists as two enantiomers, (R,R)-(-)- and (S,S)-(+)-reboxetine.
(4Z)-Decenoylcarnitine
(4Z)-Decenoylcarnitine is an acylcarnitine. More specifically, it is an (4Z)-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (4Z)-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (4Z)-decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (4Z)-decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
cis-4-Decenoyl carnitine
cis-4-Decenoyl carnitine is an acylcarnitine. More specifically, it is an cis-4-decenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. cis-4-Decenoyl carnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine cis-4-Decenoyl carnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular cis-4-Decenoyl carnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(6E)-8-Methylnon-6-enoylcarnitine
(6E)-8-Methylnon-6-enoylcarnitine is an acylcarnitine. More specifically, it is an (6E)-8-methylnon-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (6E)-8-Methylnon-6-enoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (6E)-8-Methylnon-6-enoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3,4-dimethylidenehexanedioylcarnitine
3,4-dimethylidenehexanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylidenehexanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylidenehexanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylidenehexanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Decenoylcarnitine
3-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 3-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
6-Decenoylcarnitine
6-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 6-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
7-Decenoylcarnitine
7-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-7-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 7-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
5-Decenoylcarnitine
5-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 5-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
2-Decenoylcarnitine
2-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-2-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 2-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(8Z)-Decenoylcarnitine
(8Z)-Decenoylcarnitine is an acylcarnitine. More specifically, it is an (8Z)-dec-8-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (8Z)-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (8Z)-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular (8Z)-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852) and familial mediterranean fever (PMID: 29900937). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Octa-3,5-dienedioylcarnitine
Octa-3,5-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-3,5-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,5-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,5-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Octa-2,6-dienedioylcarnitine
Octa-2,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-2,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-2,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-2,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(2Z,4Z)-Octa-2,4-dienedioylcarnitine
(2Z,4Z)-octa-2,4-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2Z,4Z)-octa-2,4-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2Z,4Z)-octa-2,4-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2Z,4Z)-octa-2,4-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
Octa-3,6-dienedioylcarnitine
Octa-3,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an octa-3,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. octa-3,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine octa-3,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxynona-4,7-dienoylcarnitine
3-hydroxynona-4,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-4,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-4,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-4,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxynona-5,7-dienoylcarnitine
3-hydroxynona-5,7-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-5,7-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-5,7-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-5,7-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
3-Hydroxynona-4,6-dienoylcarnitine
3-hydroxynona-4,6-dienoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxynona-4,6-dienoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-hydroxynona-4,6-dienoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-hydroxynona-4,6-dienoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].
(-)-Armepavine
C19H23NO3 (313.16778480000005)
(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
alpha-(Dimethylaminomethyl)-2-(3-ethyl-5-methyl-4-isoxazolyl)-1H-indole-3-methanol
10-(2-(Diethylamino)propyl)-10H-pyrido(3,2-b)(1,4)benzothiazine
C18H23N3S (313.16125980000004)
Heliotron
Mavoglurant
C19H23NO3 (313.16778480000005)
Myofedrin
C19H23NO3 (313.16778480000005)
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents
Norethindrone oxime
Ricasetron
5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenzazonin-2-ol|5,6,8,9-tetrahydro-3,12-dimethoxy-7-methyl-dibenz[d,f]azonin-2-ol|Laurifinin|laurifinine
C19H23NO3 (313.16778480000005)
7,8-Dimethoxy-2-methyl-1-(4-hydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline
C19H23NO3 (313.16778480000005)
retronecine (S)-2-hydroxy-2-((S)-1-hydroxyethyl)-4-methyl-pentanoyl ester|Retronecine 2S-hydroxy-2S-(1S-hydroxyethyl)-4-methylpentanoyl ester
15,16-methanediyldioxy-3beta-methoxy-11a-homo-erythrin-1(6)-ene|3-epi-epischellhammericine|3-epi-schelhammereicine|3-epi-Schelhammericin|3-epi-schelhammericine|3-Epischelhammericine
C19H23NO3 (313.16778480000005)
(+-)Petalinjodid|1-(4-Methoxy-benzyl)-1,2,3,4-tetrahydro-7-methoxy-2-methyl-8-isochinolinol|1-(4-Methoxy-benzyl)-8-hydroxy-7-methoxy-2-methyl-1,2,3,4-tetrahydro-isochinolin|1-(4-Methoxybenzyl)-7-methoxy-2-methyl-1,2,3,4-tetrahydro-8-isochinolinol|7-methoxy-1-(4-methoxy-benzyl)-2-methyl-1,2,3,4-tetrahydro-isoquinolin-8-ol|Gorchacoine|Gortschakoin|Petalinjodid
C19H23NO3 (313.16778480000005)
7-(1,3-benzodioxol-5-yl)-1-piperidin-1-ylhepta-2,4-dien-1-one
C19H23NO3 (313.16778480000005)
(n-Undecanon-10)-2-chinolon-4|2-(10-oxo-undecyl)-1H-quinolin-4-one|2-(10-Oxoundecyl)-4(1H)-quinolinone
(2E,6E)-7-(benzo[d][1,3]dioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one|4,5-dihydropiperettine|pipersintenamide
C19H23NO3 (313.16778480000005)
alpha-Codeimethine
C19H23NO3 (313.16778480000005)
relative retention time with respect to 9-anthracene Carboxylic Acid is 0.481 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.478
Maprotiline Hydrochloride
C20H24ClN (313.15971740000003)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators
ethylmorphine
C19H23NO3 (313.16778480000005)
R - Respiratory system > R05 - Cough and cold preparations > R05D - Cough suppressants, excl. combinations with expectorants > R05DA - Opium alkaloids and derivatives D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D019141 - Respiratory System Agents > D000996 - Antitussive Agents D002491 - Central Nervous System Agents > D000700 - Analgesics S - Sensory organs > S01 - Ophthalmologicals
PC(O-2:0/O-2:0)
C12H28NO6P (313.16541580000006)
PC(O-4:0/0:0)[U]
C12H28NO6P (313.16541580000006)
15-Lipoxygenase Inhibitor 1
4-MMPB is a selective inhibitor of 15-lipoxygenase, with an IC50 of 18 μM. 4-MMPB has IC50s of 19.5 μM and 19.1 μM for soybean 15-lipoxygenase (SLO) and human 15-lipoxygenase-1 (15-LOX-1), respectively. 4-MMPB has potential for the research of prostate cancer[1][2][3][4].
Reboxetine
C19H23NO3 (313.16778480000005)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C185721 - Norepinephrine Reuptake Inhibitor C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents N - Nervous system > N06 - Psychoanaleptics > N06A - Antidepressants D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators
Codeine methyl ether
C19H23NO3 (313.16778480000005)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
CAR 10:1
tert-Butyl 4-(isoquinolin-3-yl)piperazine-1-carboxylate
N,N,N-[(Vinylsilanetriyl)tris(oxy)]tri(2-butanimine)
C14H27N3O3Si (313.18215919999994)
N-Desmethylterbinafine hydrochloride
C20H24ClN (313.15971740000003)
Sematilide
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents
3-Quinolinecarboxylic acid, 1-cyclopropyl-1,4-dihydro-4-oxo-7-(1-piperazinyl)
3-AMINO-N,N-DIETHYL-4-MORPHOLIN-4-YL-BENZENESULFONAMIDE
tert-butyl 4-(4-amino-2,6-difluorophenyl)piperazine-1-carboxylate
Oxilorphan
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids C78272 - Agent Affecting Nervous System > C681 - Opiate Antagonist
ethyl 1-(6-formylquinazolin-4-yl)piperidine-3-carboxylate
2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-
C19H23NO3 (313.16778480000005)
2H-Pyrrol-2-one, 4-acetyl-5-cyclohexyl-1,5-dihydro-3-hydroxy-1-(4-methylphenyl)-, (5R)-
C19H23NO3 (313.16778480000005)
ethyl 1-(6-formylquinazolin-4-yl)piperidine-4-carboxylate
7-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one
C19H23NO3 (313.16778480000005)
6-(3-azaspiro[5.5]undecan-9-yloxy)chromen-2-one
C19H23NO3 (313.16778480000005)
5-METHYL-N2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYL)PYRIMIDINE-2,4-DIAMINE
Xenysalate
C19H23NO3 (313.16778480000005)
D - Dermatologicals > D11 - Other dermatological preparations > D11A - Other dermatological preparations > D11AC - Medicated shampoos C78284 - Agent Affecting Integumentary System > C29700 - Astringent
(17alpha)-17-hydroxy-3-oxoandrost-4-ene-17-carbonitrile
Fenalcomine
C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
Benzenemethanaminium,N,N,N-tripropyl-, bromide (1:1)
C16H28BrN (313.14049880000005)
1-(4-methoxyphenyl)-2-[2-(4-methoxyphenyl)ethylamino]propan-1-one
C19H23NO3 (313.16778480000005)
Bis(4-methoxyphenyl)[(2S)-2-pyrrolidinyl]methanol
C19H23NO3 (313.16778480000005)
N-[2-Isopropylthiazol-4-ylmethyl(methyl)carbamoyl]-L-valine
Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(2-methylphenyl)-1-piperazinyl]
Methanone, (3,5-dimethyl-4-isoxazolyl)[4-(2,3-dimethylphenyl)-1-piperazinyl]-
TERT-BUTYL 4-(ISOQUINOLIN-5-YL)PIPERAZINE-1-CARBOXYLATE
2,2-dimethyl-N-[(4-propan-2-yloxyphenyl)methyl]oxan-4-amine,hydrochloride
C17H28ClNO2 (313.18084580000004)
tert-Butyl 3-(2-(tert-butoxy)-2-oxoethyl)-4-oxopiperidine-1-carboxylate
(4R)-2-Methyl-4,5,5-triphenyl-1,3,2-oxazaborolidine
ethyl 2-(dibenzylamino)-3-hydroxypropanoate
C19H23NO3 (313.16778480000005)
Methanone, (3-ethyl-5-methyl-4-isoxazolyl)[4-(3-methylphenyl)-1-piperazinyl]
2H,4H-[1,3]Dioxolo[4,5-h]indolo[7a,1-a][2]benzazepine,1,5,6,12,13,14-hexahydro-13-methoxy-, (11bS,13S)-
C19H23NO3 (313.16778480000005)
6-(2-(PYRIDIN-2-YL)-5,6-DIHYDRO-4H-PYRROLO[1,2-B]PYRAZOL-3-YL)QUINOXALINE
(S)-ethyl 2-(tert-butoxycarbonylamino)-5-oxonon-8-enoate
13-Ethyl-17-hydroxy-18,19-dinorpregn-5(10)-en-20-yn-3-one
3-(Dimethylamino)-1-(6-(3-methoxyphenyl)-7,7a-dihydroimidazo[2,1-b]oxazol-5-yl)prop-2-en-1-one
rac 5-Carboxy Desisopropyl Tolterodine
C19H23NO3 (313.16778480000005)
N-(2,3,5,6-TetraMethylphenylsulfonyl)valine Monohydrate
Venlafaxine hydrochloride
C17H28ClNO2 (313.18084580000004)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D000068760 - Serotonin and Noradrenaline Reuptake Inhibitors D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent D049990 - Membrane Transport Modulators
Acecainide hydrochloride
C15H24ClN3O2 (313.15569539999996)
C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C93038 - Cation Channel Blocker
tert-butyl N-(benzenesulfonyl)-N-(2-methylpropyl)carbamate
BenzeneMethanol, 3-[5-[(1-Methyl-4-piperidinyl)Methoxy]-2-pyrimidinyl]-
mavoglurant
C19H23NO3 (313.16778480000005)
C78272 - Agent Affecting Nervous System Mavoglurant (AFQ056) is a potent, selective, non-competitive and orally active mGluR5 antagonist, with an IC50 of 30 nM. Mavoglurant shows a >300 fold selectivity for the mGluR5 over all targets (238) tested. Mavoglurant can be used for the research of Fragile X syndrome (FXS), and L-dopa induced dyskinesias in Parkinson's disease[1][1][2]. Mavoglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
4-Benzyloxy-2-piperidine-1-yl-pyrimidine-5-boronic acid
1-[1-(3,4-dichlorophenyl)cyclobutyl]-N,N,3-trimethylbutan-1-amine
C17H25Cl2N (313.13639500000005)
Amitriptyline Hydrochloride
C20H24ClN (313.15971740000003)
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D002491 - Central Nervous System Agents > D000700 - Analgesics D049990 - Membrane Transport Modulators Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with Kis of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a Ki of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity[1][2][3].
N-cyclopentyl-5-(3,4-dimethoxyphenyl)-2-methylpyrimidin-4-amine
tert-Butyl 3-(piperazin-1-yl)azetidine-1-carboxylate dihydrochloride
C12H25Cl2N3O2 (313.13237300000003)
tert-butyl 4-(3-(ethoxycarbonyl)-2-oxopropyl)piperidine-1-carboxylate
TERT-BUTYL 4-(ISOQUINOLIN-1-YL)PIPERAZINE-1-CARBOXYLATE
4-(Cyclohexyliminomethyl)benzeneboronic acid pinacol ester
6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
C19H23NO3 (313.16778480000005)
4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]piperidine,hydrochloride
oxyfedrine
C19H23NO3 (313.16778480000005)
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D020011 - Protective Agents > D002316 - Cardiotonic Agents
Irdabisant
C254 - Anti-Infective Agent Irdabisant (CEP-26401) is a selective, orally active and blood-brain barrier (BBB) penetrant histamine H3 receptor (H3R) inverse agonist/inverse agonist with Ki values of 7.2 nM and 2.0 nM for rat H3R and human H3R, respectively. Irdabisant has relatively low inhibitory activity against hERG current with an IC50 of 13.8 μM. Irdabisant has cognition-enhancing and wake-promoting activities in the rat social recognition model. Irdabisant can be used to research schizophrenia or cognitive impairment[1][2].
2-(6-methylpyridin-2-yl)-N-pyridin-4-ylquinazolin-4-amine
7,8-Dihydro-6-hydroxymethyl-7-methyl-7-[2-phenylethyl]-pterin
C16H19N5O2 (313.15386739999997)
erythro-9-(2-Hydroxy-3-nonyl)adenine hydrochloride
C14H24ClN5O (313.16692839999996)
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D000890 - Anti-Infective Agents > D000998 - Antiviral Agents D004791 - Enzyme Inhibitors
Indisetron
C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist > C94726 - 5-HT3 Receptor Antagonist
7-Isoquinolinol, 1,2,3,4-tetrahydro-6-methoxy-1-((4-methoxyphenyl)methyl)-2-methyl-, (S)-
C19H23NO3 (313.16778480000005)
5-(Dodecylthio)-1h-1,2,3-Triazole-4-Carboxylic Acid
5-[(4-Aminocyclohexyl)amino]-7-(propan-2-ylamino)pyrazolo[1,5-A]pyrimidine-3-carbonitrile
5-tert-butyl-N-(2,3-dihydro-1-benzouran-5-ylmethyl)-2-methylpyrazole-3-carboxamide
14-[2-(Dimethylamino)ethyl]-11-methoxy-15-oxatetracyclo[10.2.1.05,14.08,13]pentadeca-3,6,8(13),9,11-pentaen-2-ol
C19H23NO3 (313.16778480000005)
1-isopropyl-3-(3,4-dimethoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine
C16H19N5O2 (313.15386739999997)
(1R,9S,10R)-17-(Cyclopropylmethyl)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene-4,10-diol
[(8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl 2-hydroxy-2-(1-methoxyethyl)-3-methylbutanoate
(1R,2R,5R,8R,9S,10R,11S)-11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-13-ene-9-carboxylate
C19H21O4- (313.14397660000003)
(2S)-2-[(E)-[(2S)-2-amino-3-(4-hydroxyphenyl)propylidene]amino]-3-(4-hydroxyphenyl)propanal
C18H21N2O3+ (313.15520960000003)
(2S)-2-[[(2E,6E)-7-carboxy-3-methylocta-2,6-dienyl]amino]pentanedioic acid
3-[(E)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate
(E)-3-hydroxy-4-oxo-3-[(trimethylazaniumyl)methyl]tridec-5-enoate
3-Decenoylcarnitine
3-Decenoylcarnitine is an acylcarnitine. More specifically, it is an dec-3-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279 ). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review (PMID: 35710135 ), acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Decenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Decenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494 ). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. In particular 3-Decenoylcarnitine is elevated in the blood or plasma of individuals with overweight (PMID: 30322392 ). It is also decreased in the blood or plasma of individuals with schizophrenia (PMID: 31161852 ) and familial mediterranean fever (PMID: 29900937 ). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279 ). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available (PMID: 35710135 ).
(3R)-3-[(Z)-dec-4-enoyl]oxy-4-(trimethylazaniumyl)butanoate
2-[(2-Ethoxyphenoxy)-phenylmethyl]morpholine
C19H23NO3 (313.16778480000005)
N-[(1-ethylpyrrolidin-2-yl)methyl]-8-fluoro-5H-pyrimido[5,4-b]indol-4-amine
3-[2-(1-piperidinyl)ethylthio]-5H-[1,2,4]triazino[5,6-b]indole
N-(2,4-dimethylphenyl)-4-[2-(2-furylmethylene)hydrazino]-4-oxobutanamide
4-(2,3-dihydro-1H-indol-1-yl)-1-phenyl-1H-pyrazolo[3,4-d]pyrimidine
Norajmaline(1+)
An organic cation obtained by protonation of the tertiary amino group of norajmaline; major structure at pH 7.3.
3-Butyl-5-(4-morpholinylmethyl)-2-oxo-3-oxolanecarboxylic acid ethyl ester
N,N-dimethyl-3-[(2-phenyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)thio]-1-propanamine
C18H23N3S (313.16125980000004)
N-(6-Butyrylamino-pyridin-3-yl)-2-methoxy-benzamide
1-cyclohexyl-N-(3-methylbutyl)-5-benzimidazolecarboxamide
3-[5-(4-Methylphenyl)-1-(2-oxolanylmethyl)-2-pyrrolyl]propanoic acid
C19H23NO3 (313.16778480000005)
[2-[(2,6-dimethyl-4-morpholinyl)-oxomethyl]phenyl]-(1H-imidazol-2-yl)methanone
7-methyl-3-(4-morpholinyl)-1-(prop-2-enylamino)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile
1-(2-Fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea
(2R)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
C19H23NO3 (313.16778480000005)
6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine
1-(4-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone
2-hydroxy-2-[(1R)-1-methoxyethyl]-3-methylbutanoic acid [(7S,8R)-7-hydroxy-5,6,7,8-tetrahydro-3H-pyrrolizin-1-yl]methyl ester
5,5-Diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one
3-Methoxyestra-1,3,5(10)-triene-16,17-dione 16-oxime
C19H23NO3 (313.16778480000005)
1-[2-(Dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexan-1-ol;hydron;chloride
C17H28ClNO2 (313.18084580000004)
1-[(1-Tert-butyl-5-tetrazolyl)-phenylmethyl]-4-methylpiperidine
3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-cyclopropylpropanamide
9-cis-4-Oxoretinoate
C20H25O3- (313.18035999999995)
A retinoid anion that is the conjugate base of 9-cis-4-oxoretinoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.
15-deoxy-Delta(12,14)-prostaglandin J3(1-)
C20H25O3- (313.18035999999995)
A prostaglandin carboxylic acid anion that is the conjugate base of 15-deoxy-Delta(12,14)-prostaglandin J3. obtained by deprotonation of the carboxy group; major species at pH 7.3.
1-(3-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone
1-(2-Fluorophenyl)-3-(4-morpholinyl)-2-phenyl-1-propanone
(3-Butoxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate
C12H28NO6P (313.16541580000006)
2-Aminoethyl (3-heptoxy-2-hydroxypropyl) hydrogen phosphate
C12H28NO6P (313.16541580000006)
6-O-METHYLCODEINE
C19H23NO3 (313.16778480000005)
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids
O-decenoylcarnitine
An O-acylcarnitine in which the acyl group is specified as decenoyl (position of double bond not specified).
O-decenoyl-L-carnitine
An O-acyl-L-carnitine that is L-carnitine having decenoyl group as the acyl substituent in which the position of the double bond is unspecified.
O-[(4Z)-decenoyl]carnitine
An O-decenoylcarnitine having (4Z)-decenoyl as the acyl substituent.
Zenidolol (hydrochloride)
C17H28ClNO2 (313.18084580000004)
Zenidolol (ICI-118551) hydrochloride is a highly selective β2 adrenergic receptor antagonist, with Kis of 0.7, 49.5 and 611 nM for β2, β1 and β3 receptors, respectively.
n-{[8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid
(3s,6r)-5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one
hexahydro-1h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(2-methylpropyl)pentanoate
(7as)-1-({[(2r)-2-hydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoyl]oxy}methyl)-5,6,7,7a-tetrahydro-3h-pyrrolizin-4-ium-4-olate
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol
12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one
5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol
(1s,2r,5s,8r,9s,11r,13r,14s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-2,13-diol
(1s,5s,8r,9s,11r,13s,14s,17r,18r)-5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,17-diol
(8s,12r,13s)-12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one
5-methyl-12-methylidene-7-azahexacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁹,¹⁴.0¹⁴,¹⁸]nonadec-6-ene-13,18-diol
(2e,4e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one
C19H23NO3 (313.16778480000005)
(1r,3s,5r,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol
(2e,6e)-7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one
C19H23NO3 (313.16778480000005)
[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate
1- [α-(1- adamantyl)]- phenyl thiosemicarbazide
C18H23N3S (313.16125980000004)
{"Ingredient_id": "HBIN002265","Ingredient_name": "1- [\u03b1-(1- adamantyl)]- phenyl thiosemicarbazide","Alias": "NA","Ingredient_formula": "C18H23N3S","Ingredient_Smile": "C1C2CC3CC1CC(C2)(C3)C(=NNC(=S)N)C4=CC=CC=C4","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "35120","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
2-(decan-9-one)-n-methyl-4-quinolone
{"Ingredient_id": "HBIN005514","Ingredient_name": "2-(decan-9-one)-n-methyl-4-quinolone","Alias": "NA","Ingredient_formula": "C20H27NO2","Ingredient_Smile": "CC(=O)CCCCCCCCC1=CC(=O)C2=CC=CC=C2N1C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4835","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
3-epischelhammericine
C19H23NO3 (313.16778480000005)
{"Ingredient_id": "HBIN008501","Ingredient_name": "3-epischelhammericine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "COC1CC=C2CCN3C2(C1)C4=CC5=C(C=C4CCC3)OCO5","Ingredient_weight": "313.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "7013","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "296196","DrugBank_id": "NA"}
3-epishelhammericine
C19H23NO3 (313.16778480000005)
{"Ingredient_id": "HBIN008502","Ingredient_name": "3-epishelhammericine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "Not Available","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "25791","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
amuronine
C19H23NO3 (313.16778480000005)
{"Ingredient_id": "HBIN015931","Ingredient_name": "amuronine","Alias": "NA","Ingredient_formula": "C19H23NO3","Ingredient_Smile": "CN1CCC2=CC(=C(C3=C2C1CC34CCC(=O)C=C4)OC)OC","Ingredient_weight": "313.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "1101","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "12306126","DrugBank_id": "NA"}
(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate
(1s,20s)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene
C19H23NO3 (313.16778480000005)
(7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-4-methylpentanoate
20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene
C19H23NO3 (313.16778480000005)
(1s,5s,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol
(5r,9s,11s,16s,17r,18r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-10,16-diol
3-({[(1z)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one
C19H23NO3 (313.16778480000005)
4,15-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-3-ol
C19H23NO3 (313.16778480000005)
(1r,3s,5s,8r,9s,11r,13r,14s,16s,17r,18s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol
5-hydroxy-3-(1h-indol-3-ylmethyl)-1-methyl-6-(2-methylpropyl)-3,6-dihydropyrazin-2-one
1-{2,4-dihydroxy-4-isopropyl-6-oxa-3-azabicyclo[3.1.0]hex-2-en-1-yl}-2-hydroxy-2-methyloctan-1-one
3-[(3r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-3-yl]quinazolin-4-one
4-hydroxy-2-[(4z)-undec-4-en-1-yl]quinolin-1-ium-1-olate
(1s,12s,14r)-9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
C19H23NO3 (313.16778480000005)
4-hydroxy-2-(undec-4-en-1-yl)quinolin-1-ium-1-olate
(1s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,17-tetraene
C19H23NO3 (313.16778480000005)
7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,4-dien-1-one
C19H23NO3 (313.16778480000005)
6-hydroxy-4-[(2r,3r)-2-hydroxy-3-[(2s,3s)-2-hydroxy-3-methyl-4-methylideneoxolan-2-yl]-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one
(1s,17r,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene
C19H23NO3 (313.16778480000005)
(1r)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
C19H23NO3 (313.16778480000005)
1-[(4-hydroxyphenyl)methyl]-6-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-7-olate
C19H23NO3 (313.16778480000005)
(1s,17s,20r)-20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene
C19H23NO3 (313.16778480000005)
4-{[(1s)-7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol
C19H23NO3 (313.16778480000005)
(5r)-3-({[(1z,6s)-6-[(1e,3e)-hepta-1,3-dien-1-yl]-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one
C19H23NO3 (313.16778480000005)
n-[9-(hex-2-en-1-yl)-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid
(8s,12s,13s)-12,13-dihydroxy-13-(3-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one
7,8,11-trimethoxy-2h,4h,5h,10h,11h-indolo[7a,1-a]isoquinoline
C19H23NO3 (313.16778480000005)
(1s,4's)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one
C19H23NO3 (313.16778480000005)
(1s,4'r)-10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one
C19H23NO3 (313.16778480000005)
(2s,3s,4r)-3-methyl-2-[(1e,3e)-4-phenylbuta-1,3-dien-1-yl]piperidin-4-yl 2-methylpropanoate
10',11'-dimethoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraen-4-one
C19H23NO3 (313.16778480000005)
(1s)-7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol
C19H23NO3 (313.16778480000005)
5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(1-methoxyethyl)-3-methylbutanoate
[(7r,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate
4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2(7),3,5,13,15-hexaen-3-ol
C19H23NO3 (313.16778480000005)
1-[2-(diethylamino)ethyl]-4-methoxy-9h-pyrido[3,4-b]indol-8-ol
[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2r,3r)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylpentanoate
7-(2h-1,3-benzodioxol-5-yl)-1-(piperidin-1-yl)hepta-2,6-dien-1-one
C19H23NO3 (313.16778480000005)
(1r,5s,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol
12,13-dihydroxy-13-(1-methylimidazol-4-yl)-1-azatricyclo[6.4.2.0²,⁷]tetradeca-2,4,6-trien-9-one
(1s,5s,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol
7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl 2-hydroxy-2-(1-hydroxyethyl)-3-methylpentanoate
5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-3,13-diol
6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one
C19H23NO3 (313.16778480000005)
(1s,5r,8r,9s,11r,13r,14r,16s,17r,18s,19s)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-13,19-diol
3-({[6-(hepta-1,3-dien-1-yl)-2-oxocyclohex-3-en-1-ylidene]methyl}amino)-5-methyl-5h-furan-2-one
C19H23NO3 (313.16778480000005)
(1r,5r,8r,9s,11r,14s,16r,17r,18r,19r)-5-methyl-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecane-16,19-diol
20-methoxy-5,7-dioxa-14-azapentacyclo[12.7.0.0¹,¹⁷.0²,¹⁰.0⁴,⁸]henicosa-2,4(8),9,18-tetraene
C19H23NO3 (313.16778480000005)
(1s)-1-[2-(4-hydroxyphenyl)ethyl]-7-methoxy-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol
C19H23NO3 (313.16778480000005)
(1r)-6-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-7-ol
C19H23NO3 (313.16778480000005)
n-[(1s,9s,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid
(1s)-6,7-dimethoxy-1-[(4-methoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinoline
C19H23NO3 (313.16778480000005)
1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate
C19H23NO3 (313.16778480000005)
n-[(1s,9r,10r)-9-[(2z)-hex-2-en-1-yl]-10-methyl-5,7-diazatricyclo[6.3.1.0⁴,¹²]dodeca-4(12),5,7-trien-6-yl]ethanimidic acid
n-{[(5e)-8,11-bis(prop-2-en-1-yl)-1,7-diazatetracyclo[7.2.1.0²,⁷.0⁶,¹¹]dodecan-5-ylidene]methyl}ethanimidic acid
n-(5-carbamimidamido-1-oxopentan-2-yl)-2-[(1-hydroxyethylidene)amino]-4-methylpentanimidic acid
(1s)-1-[(4-hydroxyphenyl)methyl]-7-methoxy-2,2-dimethyl-3,4-dihydro-1h-isoquinolin-2-ium-8-olate
C19H23NO3 (313.16778480000005)
5-hydroxy-3-{4-[(3-methylbut-2-en-1-yl)oxy]phenyl}-4-(2-methylpropyl)pyrrol-2-one
C19H23NO3 (313.16778480000005)
3-{[(1r)-6,7-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl]methyl}phenol
C19H23NO3 (313.16778480000005)
7-methoxy-1-[(4-methoxyphenyl)methyl]-2-methyl-3,4-dihydro-1h-isoquinolin-6-ol
C19H23NO3 (313.16778480000005)
(7as)-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-ylmethyl (2r)-2,3-dihydroxy-2-[(1r)-1-methoxyethyl]-3-methylbutanoate
3-[(4r,9s,9ar)-9-hydroxy-2-oxo-octahydroquinolizin-4-yl]quinazolin-4-one
(1s,5'r)-12'-hydroxy-11'-methoxy-6'-methyl-6'-azaspiro[cyclohexane-1,2'-tricyclo[7.3.1.0⁵,¹³]tridecane]-1'(12'),2,9'(13'),10'-tetraen-4-one
C19H23NO3 (313.16778480000005)
2-hexyl-3a,4,6-trihydroxy-6-isopropyl-2-methyl-6ah-furo[2,3-c]pyrrol-3-one
6-hydroxy-4-[2-hydroxy-3-(2-hydroxy-3-methyl-4-methylideneoxolan-2-yl)-3-methoxypropyl]-4,5-dihydro-3h-pyridin-2-one
(1r,7ar)-7-(hydroxymethyl)-2,3,5,7a-tetrahydro-1h-pyrrolizin-1-yl (2s,3s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylpentanoate
5,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-4-ol
C19H23NO3 (313.16778480000005)
(2r,9r)-6,8-dimethoxy-9-(methylamino)-2-(prop-1-en-2-yl)-1h,2h,3h,9h-cyclopenta[b]naphthalen-4-one
C19H23NO3 (313.16778480000005)
3-(9-hydroxy-2-oxo-octahydroquinolizin-4-yl)quinazolin-4-one
(2r)-2-[(4r)-1-(2,4-dihydroxybutyl)-2-iminoimidazolidin-4-yl]-6-methylhept-5-enoic acid
[(7s,7ar)-7-hydroxy-5,6,7,7a-tetrahydro-3h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-4-methylpentanoate
(2r,3r,12br)-3-ethyl-2-(2-hydroxyethyl)-5-methyl-1h,2h,3h,4h,6h,7h,12h,12bh-indolo[2,3-a]quinolizin-5-ium
(1s,5r,8r,9s,11r,14s,16s,17s,18r,19s)-5-(hydroxymethyl)-12-methylidene-7-azaheptacyclo[9.6.2.0¹,⁸.0⁵,¹⁷.0⁷,¹⁶.0⁹,¹⁴.0¹⁴,¹⁸]nonadecan-19-ol
4,16-dimethoxy-10-methyl-10-azatricyclo[11.4.0.0²,⁷]heptadeca-1(17),2,4,6,13,15-hexaen-5-ol
C19H23NO3 (313.16778480000005)
9-methoxy-4-(prop-2-en-1-yl)-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
C19H23NO3 (313.16778480000005)
4-[(7,8-dimethoxy-2-methyl-3,4-dihydro-1h-isoquinolin-1-yl)methyl]phenol
C19H23NO3 (313.16778480000005)